Lilly backs OrsoBio’s $60M Series A for PhII trials in obesity and NASH

Or­so­Bio, a biotech fo­cused on obe­si­ty and meta­bol­ic dis­or­ders, is get­ting fi­nan­cial sup­port from one of the lead­ing drug­mak­ers in the field as Eli Lil­ly helps back its $60 mil­lion Se­ries A round.

Or­so­Bio, based in Men­lo Park, CA, is an amal­ga­ma­tion of as­sets from Gilead, Sh­iono­gi, Phenex Phar­ma­ceu­ti­cals and Astel­las, and it al­ready has can­di­dates in hu­man test­ing or clin­i­cal plans for obe­si­ty, type 2 di­a­betes, non­al­co­holic steato­hep­ati­tis, as well as oth­er in­flam­ma­to­ry liv­er and kid­ney dis­or­ders.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.